NorthStar Medical Radioisotopes has big plans in Beloit

Print Article

  • Austin Montgomery/Beloit Daily News From left: NorthStar Medical Radioisotopes CEO George Messina and VP/COO Stephen Merrick stand near the company's training area in the production facility located at its corporate headquarters in Beloit. The company will look to shift focus following its recent approval from the U.S. Food & Drug Administration.

  • 1

    Austin Montgomery/Beloit Daily News Pictured is NorthStar Medical Radioisotopes production units known as the RadioGenix system in its Beloit facility.

  • 2

    Austin Montgomery/Beloit Daily News Pictured is one of the source vessels used by NorthStar Medical Radioisotopes in its supply and transport process of its patented technology. Each vessel contains one unit to be used in radio image medical tests.

  • Austin Montgomery/Beloit Daily News From left: NorthStar Medical Radioisotopes CEO George Messina and VP/COO Stephen Merrick stand near the company's training area in the production facility located at its corporate headquarters in Beloit. The company will look to shift focus following its recent approval from the U.S. Food & Drug Administration.

  • 1

    Austin Montgomery/Beloit Daily News Pictured is NorthStar Medical Radioisotopes production units known as the RadioGenix system in its Beloit facility.

  • 2

    Austin Montgomery/Beloit Daily News Pictured is one of the source vessels used by NorthStar Medical Radioisotopes in its supply and transport process of its patented technology. Each vessel contains one unit to be used in radio image medical tests.

BELOIT - After receiving vital federal approval for proprietary technology last week, NorthStar Medical Radioisotopes looks to expand its presence in Beloit and pursue cancer and HIV therapies, according to company executives.

NorthStar got a green light from the U.S. Food and Drug Administration Feb. 8 to market its patented RadioGenix system to radiopharmacies to help in the fight against cancer, heart disease and other ailments.

The federal approval marked the first domestic production of medical radioisotope molybdenum-99 (Mo-99) in more than 25 years. The company's technology can be used to separate Mo-99 from Technetium-99 (Tc-99m), the most widely used isotope in radio-medical imaging.

NorthStar CEO George Messina said the company had been working on drug therapies when its scientific team realized the company's tech could provide the "keys to the kingdom" in the race to move away from using low-enriched uranium and the development of streamlined point-of-care offerings.

"We're looking to enhance RadioGenix and find ways to reduce the cost of its production while pursuing those therapies," Messina said Monday in an interview with the Beloit Daily News. "Pursuing these therapies would not be as difficult now."

Tc-99 is used in around 40 million procedures worldwide each year to diagnose and stage cancer, heart disease, infection and inflammation. The U.S. accounts for 50 percent of all Mo-99 and Tc-99m used in the global health care market, officials said, with 40,000 injections used daily across the U.S. in the diagnosis and treatment monitoring of heart, lung, thyroid, bone and other tissue-related diseases.

Federal approval served as a final step ahead of production, and the approval has paved the way for the company to offer on-site customer training.

By the end of this year, NorthStar will look to supply 10 percent of its possible market, with projections estimating in a few years time the company could supply up to two-thirds of the domestic supply of the valuable isotopes, according to top company officials.

The company will add a 20,000 square-foot production facility to its campus in the Gateway Business Park, while looking to hire 25 new staff to the 180-employee roster, spread across Beloit, Madison and Columbia, Missouri near a reactor used in NorthStar's production process.

As part of the company's plan to improve its RadioGenix system to align for future federal approvals related to other isotopes, NorthStar will add facilities to accompany its HIV and cancer therapy development.

"As a small company, we want to stay nimble," Messina said.

The campus will expand incrementally over the next decade in multiple phases, with the company spending in excess of $100 million towards research and development through private and public investment, including $50 million from the National Nuclear Security Administration (NNSA) agency within the U.S. Department of Energy (DOE) for two cooperative grants. Hendricks Holding Company also has been instrumental in funding the company's development.

"We are very grateful for their support," Messina said.

For more information on the company, see northstarnm.com

Print Article

Read More News

The Latest: 1 dead, damage reported after Arkansas storms

AP

February 24, 2018 at 8:19 pm | DEMOTTE, Ind. (AP) The Latest on potentially severe weather developing in parts of the US (all times local): 8:15 p.m. Authorities in northeast Arkansas say one person was killed after high...

Comments

Read More

The Latest: Colleges lend support to student protesters

AP

February 24, 2018 at 8:08 pm | NEW YORK (AP) The Latest on the backlash against the National Rifle Association after a deadly school shooting in Florida (all times local): 6:05 p.m. Dozens of college and universities are...

Comments

Read More

NRA, Florida face backlash after latest school shooting

AP

February 24, 2018 at 7:57 pm | NEW YORK (AP) The National Rifle Association, and now the State of Florida, faced a growing backlash Saturday as companies cut ties to the gun industry following the latest school massacre, and stu...

Comments

Read More

With hoops under federal probe, fans say business as usual

AP

February 24, 2018 at 8:15 pm | Arenas were packed, fans were cheering and schools were competing. In most places, it was a typical Saturday of college basketball. There was little visible hangover from the latest developments ...

Comments

Read More

Contact Us

(608) 365-8811
149 State Street
Beloit, WI 53511

©2018 Beloit Daily News Terms of Use Privacy Policy
X